GT Biopharma GTBP 深 沪
已收盘 08-01 16:00:00 美东时间
1.81
-0.050
-2.69%
华盛通- 最 高1.9186
- 今 开1.84
- 成交量 3.88万股
- 最 低 1.775
- 昨 收 1.86
- 总市值 592.41万
- 52周最高 4.10
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 1.72
- 委 比 -89.41%
- 总股本 327.30万
- 历史最高 591.99
- 量 比 0.41
- 振 幅 7.72%
- 历史最低 1.775
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 217.6% to $3.78 during Mo...
07-08 01:06
GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma appoints David C. Mun-Gavin to its Board of Directors. Mun-Gavin, a seasoned executive with global experience in private banking and oil trading, brings valuable insights as the company prepares for clinical data readouts and pipeline expansion. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE® NK cell engager platform.
06-13 13:00
GT Biopharma Expands Convertible Preferred Stock Offering
GT Biopharma ( ($GTBP) ) has provided an update. On May 12, 2025, GT Biopharma,...
05-28 04:55
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 72.6% to $0.47 during Wedne...
05-22 01:06
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results
GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.
05-19 20:30
GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the
05-16 06:20
美股大行评级 | 潜在涨幅265%！Humacyte获机构上调目标价至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1078254829883351040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Benchmark：维持Humacyte(HUMA)"买入"评级，目标价从15美元升至17美元</p> <p>• Evercore ISI集团：维持BridgeBio Pharma(BBIO)"跑赢大市"评级，目标价从45
2024-12-24 09:30
快讯 | Gt Biopharma Inc - 收到纳斯达克退市通知，因低于250万美元的股本最低要求
GT Biopharma Inc - Receives Nasdaq Delisting Notice for Falling Below $2.5 Mln ...
2024-11-28 05:07
